Evidence map›Paper›PMID 37668852›Full record

ArticleJournal of autism and developmental disorders2024

VEGF, IGF-1 and FGF-2 Serum Levels in Children and Adolescents with Autism Spectrum Disorder with and without Bipolar Disorder.

Gokce Guldiken, Ali Karayagmurlu, Canan Kucukgergin, Murat Coskun

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of autism and developmental disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. The Ambiguous Role of Growth Factors in Autism: What Do We Really Know?International journal of molecular sciences · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Gokce GuldikenHealth Ministry of Turkish Republic Reyhanlı State Hospital, Hatay, Turkey. drgokceguldiken@gmail.com.ORCID http://orcid.org/0000-0003-0639-4787
Ali KarayagmurluDepartment of Child and Adolescent Psychiatry, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-5464-2891
Canan KucukgerginDepartment of Medical Biochemistry, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-1797-5889
Murat CoskunDepartment of Child and Adolescent Psychiatry, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-4808-5870
Istanbul University · TRMinistry of Health · TR

Funding

Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi TTU-2022-38613
6 · The paper itself

Abstract

purposeTo investigate serum levels of VEGF, IGF-1 and FGF-2, and relationships with several clinical characteristics in children and adolescents with autism spectrum disorder (ASD) with and without bipolar disorder (BD).

method40 subjects with ASD + BD as study group, and 40 subjects with ASD as control group were included. Serum levels of VEGF, IGF-1, and FGF-2 were measured using commercial enzyme-linked immunosorbent assay kits.

resultsThe study group was significantly higher than the control group in terms of ASD severity, self-harming behavior and sleep disturbance. Serum VEGF and FGF-2 levels were significantly higher in the ASD + BD group than in the control group. There was no significant difference in serum IGF-1 levels between the two groups. There was no correlation between VEGF, IGF-1 and FGF-2 serum levels and ASD severity in the study group. However there was a negative correlation between VEGF levels and age at first diagnosis of BD, and a positive correlation between IGF-1 levels and the number of bipolar episodes in the study group.

conclusionGrowth factors like VEGF and FGF-2 may be potential biomarkers of bipolar disorder in young subjects with ASD. Given the difficulty of clinical management of BD in young subjects with ASD, potential biomarkers would help clinicians in the diagnosis and follow up of BD in this special population. Further research is needed whether VEGF and FGF-2 can be potential biomarkers in the clinical management of young subjects with ASD and BD.

Indexed as

Autism Spectrum DisorderBipolar DisorderFibroblast Growth Factor 2Insulin-Like Growth Factor IVascular Endothelial Growth Factor AAdolescentBiomarkersChildFemaleHumansMaleSeverity of Illness IndexBiomarkersFibroblast Growth Factor 2IGF1 protein, humanInsulin-Like Growth Factor IVascular Endothelial Growth Factor AVEGFA protein, humanAutismBiomarkerBipolarFGF-2VEGF

Identifiers

PMID37668852
OpenAlexW4386438019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.